

133 Molesworth Street PO Box 5013 Wellington 6140 New Zealand T+64 4 496 2000 W www.medsafe.govt.nz

2 November 2023

s 9(2)(a)

By email: \$9(2)(a)

Ref: H2023032360

Tēnā koe s 9(2)(a)

Response to your request for official information

Thank you for your request under the Official Information Act 1982 (the Act) to Manatū Hauora (the Ministry of Health) on 12 October 2023 for:

Total number of units of CBD oil sold each month nationally for the months from May 2023 to September 2023, inclusive.

Total number of units of THC dominant oil sold each month nationally for the months from May 2023 to September 2023, inclusive.

Total number of units of THC flower products sold each month nationally for the months from May 2023 to September 2023, inclusive.

Appended to this letter is the number of packs of unapproved medicines containing cannabis that have been verified as meeting the minimum quality standard and have been supplied under the exemption provisions in section 29 of the Medicines Act 1981 for May to September 2023. The information provided relates to products containing either cannabidiol (CBD) only, tetrahydrocannabinol (THC) only, or CBD plus THC.

The information supplied, as per the exemption provisions of section 29 of the Medicines Act 1981 is provided directly from importers/manufacturers to Medsafe. Medsafe then records the information provided by the supplier into a database, from which the information provided to you is generated. As this information is provided to Medsafe following supply of the medicine, the number of packs supplied is accurate as per the data supplied at the time this response was generated.

When conducting searches in response to requests for information relating to section 29 supply, the information is drawn from the aforementioned database, based on the active ingredient(s) in the product rather than the product name, dosage form or other features. To provide a breakdown of the information in this way could negatively affect the commercial position of those who supplied it.

When considering these data, it is important to note:

- That the number of packs supplied cannot be used to determine the number of prescriptions or the number of patients or the number of doses.
- Reporting information is supplied retrospectively and therefore the number of packs reported as supplied may change if additional reports are received.
- Sativex and Epidyolex have consent for distribution as a medicine, and so the reporting requirements associated with the supply of unapproved medicines in section 29 of the

Medicines Act do not apply. The data provided do not include the number of packs of Sativex or Epidyolex supplied.

Therefore, the specific breakdown of information you have requested has been withheld under the following sections of the Act:

- Section 9(2)(b)(ii), where its release would likely unreasonably prejudice the commercial position of the person who supplied the information; and
- Section 9(2)(ba)(i), to protect information that is subject to an obligation of confidence and
 making it available would likely prejudice the supply of similar information, or information
 from the same source.

Where information is withheld under section 9 of the Act, I have considered the countervailing public interest in release in making this decision and consider that it does not outweigh the need to withhold at this time.

I trust this information fulfils your request. If you wish to discuss any aspect of your request with us, including this decision, please feel free to contact the OIA Services Team on: oiagr@health.govt.nz.

Under section 28(3) of the Act, you have the right to ask the Ombudsman to review any decisions made under this request. The Ombudsman may be contacted by email at: info@ombudsman.parliament.nz or by calling 0800 802 602.

Please note that this response, with your personal details removed, may be published on the Manatū Hauora website at: www.health.govt.nz/about-ministry/information-releases/responses-official-information-act-requests.

Nāku noa, nā

Chris James
Group Manager

Medsafe

Number of packs of products containing cannabidiol only

2023

Month	May	Jun	Jul	Aug	Sept
No. of packs	5128	5458	5150	6143	130

Number of packs of products containing tetrahydrocannabinol only

2023

Month	May	June	July	Aug	Sept
No. of		846	1296	1058	618
packs	_	040	1290	1036	010

Number of packs of products containing both tetrahydrocannabinol and cannabidiol 2023

Month	May	Jun	July	Aug	Sept
No. of	5677	8834	9445	8846	402
packs	3077	0034	9443	0040	402

When considering this data, it is important to note:

- That the number of packs supplied cannot be used to determine the number of prescriptions or the number of patients or the number of doses.
- Reporting information is supplied retrospectively and therefore the number of packs reported as supplied may change if additional reports are received.
- Sativex has consent for distribution as a medicine, and so the reporting requirements associated with the supply of unapproved medicines in section 29 of the Medicines Act 1981 do not apply. The data provided do not include the number of packs of Sativex supplied.